anti-NY-ESO-1 TCR T-cell therapy siTCR (Takara Bio)

N/A

Report date: 2025/01/26 17:02:14

Base Information

Drug Nameanti-NY-ESO-1 TCR T-cell therapy siTCR (Takara Bio)

Drug Alias Nameallogeneic HLA class I-deficient anti-NY-ESO-1 TCR T-cell therapy (Takara Bio)

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionCancer/testis antigen 1 modulators

TargetsCancer/testis antigen 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTakara Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesTakara Bio Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A